finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Brainstorm Cell Therapeutics stock

Own Brainstorm Cell Therapeutics stock in just a few minutes.

Buy Brainstorm Cell Therapeutics (BCLI)
Avatar
Jing Jun Ma
Posted
Fact checked

Brainstorm Cell Therapeutics Inc is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Brainstorm Cell Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. BCLI shares summary
  2. Compare share dealing platforms
  3. Is BCLI stock a buy or sell?
  4. Stock performance over time
  5. Can I short BCLI shares?
  6. Brainstorm Cell Therapeutics's financials
  7. How volatile are BCLI shares?
  8. Does Brainstorm Cell Therapeutics pay a dividend?
  9. Have BCLI shares ever split?
  10. Other common questions

Brainstorm Cell Therapeutics share price

Use our graph to track the performance of BCLI stocks over time.

Brainstorm Cell Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$2.97 - $17.95
50-day moving average $3.72
200-day moving average $6.10
Wall St. target price$11.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.88

Buy Brainstorm Cell Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Brainstorm Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Brainstorm Cell Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Brainstorm Cell Therapeutics financials

Gross profit TTM $0
Return on assets TTM -56.84%
Return on equity TTM -134.3%
Profit margin 0%
Book value $1.00
Market capitalisation $125.5 million

TTM: trailing 12 months

Shorting Brainstorm Cell Therapeutics shares

There are currently 3.7 million Brainstorm Cell Therapeutics shares held short by investors – that's known as Brainstorm Cell Therapeutics's "short interest". This figure is 16.5% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Brainstorm Cell Therapeutics shares can be evaluated.

Brainstorm Cell Therapeutics's "short interest ratio" (SIR)

Brainstorm Cell Therapeutics's "short interest ratio" (SIR) is the quantity of Brainstorm Cell Therapeutics shares currently shorted divided by the average quantity of Brainstorm Cell Therapeutics shares traded daily (recently around 975277.39361702). Brainstorm Cell Therapeutics's SIR currently stands at 3.76. In other words for every 100,000 Brainstorm Cell Therapeutics shares traded daily on the market, roughly 3760 shares are currently held short.

However Brainstorm Cell Therapeutics's short interest can also be evaluated against the total number of Brainstorm Cell Therapeutics shares, or, against the total number of tradable Brainstorm Cell Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brainstorm Cell Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Brainstorm Cell Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1163% of the tradable shares (for every 100,000 tradable Brainstorm Cell Therapeutics shares, roughly 116 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brainstorm Cell Therapeutics.

Find out more about how you can short Brainstorm Cell Therapeutics stock.

Brainstorm Cell Therapeutics share dividends

We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.

Have Brainstorm Cell Therapeutics's shares ever split?

Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.

Brainstorm Cell Therapeutics share price volatility

Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $2.97 up to $17.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is 0.0783. This would suggest that Brainstorm Cell Therapeutics's shares are less volatile than average (for this exchange).

Brainstorm Cell Therapeutics overview

Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site